Abstract
Liposomes, which are artificial phospholipid vesicles with a bilayer membrane structure, have been developed and evaluated as a promising delivery system for vaccines. Here, we describe a procedure for the encapsulation of lipopeptide vaccines into liposomes. A liposomal formulation of lipid-core peptide was prepared via thin-film hydration followed by extrusion. The physicochemical properties of the liposomes, including their size, polydispersity, surface charge, and morphology, were analyzed using dynamic light scattering and transmission electron microscopy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Giddam AK, Zaman M, Skwarczynski M, Toth I (2012) Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomedicine 7(12):1877–1893. https://doi.org/10.2217/nnm.12.157
Nordly P, Madsen HB, Nielsen HM, Foged C (2009) Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin Drug Deliv 6(7):657–672. https://doi.org/10.1517/17425240903018863
BenMohamed L, Wechsler SL, Nesburn AB (2002) Lipopeptide vaccines—yesterday, today, and tomorrow. Lancet Infect Dis 2(7):425–431. https://doi.org/10.1016/s1473-3099(02)00318-3
Abdul Ghaffar K, Kumar Giddam A, Zaman M, Skwarczynski M, Toth I (2014) Liposomes as nanovaccine delivery systems. Curr Top Med Chem 14(9):1194–1208
Bovier PA (2008) Epaxal®: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 7(8):1141–1150
Marasini N, Ghaffar KA, Skwarczynski M, Toth I (2017) Liposomes as a vaccine delivery system. In: Skwarczynski M, Toth I (eds) Micro- and nanotechnology in vaccine development. William Andrew, Norwich, pp 221–239
Bartlett S, Eichenberger RM, Nevagi RJ, Ghaffar KA, Marasini N, Dai Y, Loukas A, Toth I, Skwarczynski M (2020) Lipopeptide-based oral vaccine against hookworm infection. J Infect Dis 221(6):934–942. https://doi.org/10.1093/infdis/jiz528
Ghaffar KA, Marasini N, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I (2017) The role of size in development of mucosal liposome-lipopeptide vaccine candidates against group A Streptococcus. Med Chem 13:22–27
Marasini N, Giddam AK, Ghaffar KA, Batzloff MR, Good MF, Skwarczynski M, Toth I (2016) Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A streptococcus. Nanomedicine 11(10):1223–1236. https://doi.org/10.2217/nnm.16.36
Marasini N, Ghaffar KA, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I (2017) Highly immunogenic trimethyl chitosan-based delivery system for intranasal lipopeptide vaccines against group A streptococcus. Curr Drug Deliv 14(5):701–708
Nevagi RJ, Dai W, Khalil ZG, Hussein WM, Capon RJ, Skwarczynski M, Toth I (2019) Structure-activity relationship of group A streptococcus lipopeptide vaccine candidates in trimethyl chitosan-based self-adjuvanting delivery system. Eur J Med Chem 179:100–108. https://doi.org/10.1016/j.ejmech.2019.06.047
Azuar A, Zhao L, Hei TT, Nevagi RJ, Bartlett S, Hussein WM, Khalil ZG, Capon RJ, Toth I, Skwarczynski M (2019) Cholic acid-based delivery system for vaccine candidates against group A streptococcus. ACS Med Chem Lett 10(9):1253–1259. https://doi.org/10.1021/acsmedchemlett.9b00239
Eskandari S, Pattinson DJ, Stephenson RJ, Groves PL, Apte SH, Sedaghat B, Chandurudu S, Doolan DL, Toth I (2018) Influence of physicochemical properties of lipopeptide adjuvants on the immune response: a rationale for engineering a potent vaccine. Chem Eur J 24(39):9892–9902
Schulze K, Ebensen T, Chandrudu S, Skwarczynski M, Toth I, Olive C, Guzman CA (2017) Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection. Nanomed Nanotechnol Biol Med 13(8):2463–2474
Bartlett S, Skwarczynski M, Toth I (2020) Lipids as activators of innate immunity in peptide vaccine delivery. Curr Med Chem 27(17):2887–2901. https://doi.org/10.2174/0929867325666181026100849
Chandrudu S, Skwarczynski M, Pattinson D, Apte SH, Doolan DL, Toth I (2016) Synthesis and immunological evaluation of peptide-based vaccine candidates against malaria. Biochem Compound 4(1):6
Hussein WM, Xu J, Simerska P, Toth I (2017) Synthesis of multicomponent peptide-based vaccine candidates against group A streptococcus. Aust J Chem 70(2):184–190
Bartlett S, Skwarczynski M, Xie X, Toth I, Loukas A, Eichenberger RM (2020) Development of natural and unnatural amino acid delivery systems against hookworm infection. Precision Nanomed 3(1):471–482
Fuaad AA, Pearson MS, Pickering DA, Becker L, Zhao G, Loukas AC, Skwarczynski M, Toth I (2015) Lipopeptide nanoparticles: development of vaccines against hookworm parasite. ChemMedChem 10(10):1647–1654. https://doi.org/10.1002/cmdc.201500227
Dougall AM, Skwarczynski M, Khoshnejad M, Chandrudu S, Daly NL, Toth I, Loukas A (2014) Lipid core peptide targeting the cathepsin D hemoglobinase of Schistosoma mansoni as a component of a schistosomiasis vaccine. Hum Vaccin Immunother 10(2):399–409. https://doi.org/10.4161/hv.27057
Ahmad Fuaad AA, Roubille R, Pearson MS, Pickering DA, Loukas AC, Skwarczynski M, Toth I (2015) The use of a conformational cathepsin D-derived epitope for vaccine development against Schistosoma mansoni. Bioorg Med Chem 23(6):1307–1312. https://doi.org/10.1016/j.bmc.2015.01.033
Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, Forouzanfar MH, Longenecker CT, Mayosi BM, Mensah GA, Nascimento BR, Ribeiro ALP, Sable CA, Steer AC, Naghavi M, Mokdad AH, Murray CJL, Vos T, Carapetis JR, Roth GA (2017) Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med 377(8):713–722. https://doi.org/10.1056/NEJMoa1603693
Abdel-Aal AB, Batzloff MR, Fujita Y, Barozzi N, Faria A, Simerska P, Moyle PM, Good MF, Toth I (2008) Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. J Med Chem 51(1):167–172. https://doi.org/10.1021/jm701091d
Zaman M, Abdel-Aal AB, Fujita Y, Ziora ZM, Batzloff MR, Good MF, Toth I (2012) Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes. J Med Chem 55(19):8515–8523. https://doi.org/10.1021/jm301074n
Ghaffar KA, Marasini N, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I (2016) Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus. Acta Biomater 41:161–168. https://doi.org/10.1016/j.actbio.2016.04.012
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Yang, J., Azuar, A., Toth, I., Skwarczynski, M. (2022). Liposomes for the Delivery of Lipopeptide Vaccines. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 2412. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1892-9_15
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1892-9_15
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1891-2
Online ISBN: 978-1-0716-1892-9
eBook Packages: Springer Protocols